


AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions,
and listings, of claims in the application:

LISTING OF CLAIMS:


1-19. (canceled)

20. (new) A compound corresponding to the following
general formula (I):



wherein:

when A forms a chain with C (A-C chain) of formula (1),



then B forms a chain with D (B-D chain) of formula (1), said A-C
chain and B-D chain, being situated independently of one another,
above (α position) or below (β position) the porphyrin macrocycle
plane, or

when A forms a chain with D (A-D chain) of formula (1), then B forms a chain with C (B-C chain) of formula (1), wherein one of said A-D chain or B-C chain is situated above (α position) the porphyrin macrocycle plane, and the other A-D chain or B-C chain, is situated below (β position) the porphyrin macrocycle plane,

and wherein:

. when X represents NH, O, CO or CH₂, Y represents respectively CO, CH₂, NH, or O,

. n₁ and n₂, each independently of one another represent 1, 2, or 3,

. U represents a group of C(Z,W) or N(CHR_a-COOR_b), in which

. Z represents:

an electroattractive group such as CN, NO₂, or CO₂⁻, or


a CH₂NR₁R₂ group, in which R₁ and R₂ represent, independently of one another, H, or a linear, branched, or cyclic alkyl group, with 1 to 8 carbon atoms, or an aryl or alkylaryl group, or a specific antibody linked to the CH₂N part of said CH₂NR₁R₂ group via a spacer, or

an aryl group substituted by an SO₃R₃, SO₂R₃, p-NO₂ or o-NO₂ function, in which R₃ represents H, or a cation chosen from the alkali metals, or R₃ represents an NR₄R₅ group in which R₄ and R₅ represent, independently of one another, a linear, branched, or cyclic alkyl group, with 1 to 8 carbon atoms, or R₃ represents a para-nitro aryl group,

. W represents a CO₂⁻ or COOR₆ group in which R₆ represents H, or a linear, branched, or cyclic alkyl group, with

1 to 8 carbon atoms, or an aryl group, or an alcohol depopulated of electrons,

. or Z and W form in combination with the carbon atom which carries them a ring designated Meldrum's acid with the following formula:




. R_a corresponds to the definition previously given for R_1 , or the side chain of a natural or modified amino acid, and


. R_b corresponds to the definition previously given for R_1 , and

E represents in combination with F, and H represents in combination with G, independently of each other, $CH=CH$, or CH_2-CH_2 .


21. (new) The compound according to claim 20, wherein the chain formations of formula (1) are chosen from the following:



or



or



and the Z and W groups are:

- (i) either directed towards the interior of said compound and are situated above or below the porphyrin macrocycle plane according to whether said chain formation of formula (1) is situated respectively in α position or in β position (respectively designated $Zi\alpha$ and $Wi\alpha$, or $Zi\beta$ or $Wi\beta$), or
- (ii) directed towards the exterior of said compounds (respectively designated Ze and We).

22. (new) The compound according to claim 20, wherein A, B, C, and D are in ortho position, and/or E represents in

combination with F, and H represents in combination with G, CH₂-CH₂.


23. (new) The compound according to claim 20, wherein A forms with C (A-C chain), and B forms with D (B-D chain), chain formations of formula (1), these two chain formations being situated in α position.

24. (new) The compound according to claim 23, wherein the A-C chain formation and B-D chain formation each comprises a Zi α group and a We group, or

the A-C chain formation comprises a Zi α group and a We group, and the B-D chain formation comprises a Ze group and a Wi α group, or

the A-C chain formation and B-D chain formation each comprises a Ze group and a Wi α group.

25. (new) The compound according to claim 23 of the following formulae:



26. (new) The compound according to claim 20, wherein A forms with C an A-C chain formation of formula (1) situated in



α position, and B forms with D a B-D chain formation of formula (1) situated in β position.

27. (new) The compound according to claim 26 wherein the A-C chain formation comprises a $Zi\alpha$ group and a We group, and the B-D chain formation comprises a $Zi\beta$ group and a We group, or


the A-C chain formation comprises a Ze group and a $Wi\alpha$ group, and the B-D chain formation comprises a $Zi\beta$ group and a We group, or

the A-C chain formation comprises a Ze group and a $Wi\alpha$ group, and the B-D chain formation comprises a Ze group and a $Wi\beta$ group.

28. (new) The compound according to claim 26 of the following formulae:



or





29. (new) The compound according to claim 20, wherein A forms with D an A-D chain formation of formula (1) situated in β position, and B forms with C, a B-C chain formation of formula (1) situated in α position.

30. (new) The compound according to claim 29, wherein the A-D chain formation comprises a Ze group and a $Wi\beta$ group, and the B-C chain formation comprises a Ze group and a $Wi\alpha$ group, or


the A-D chain formation comprises a $Zi\beta$ group and a We group, and the B-C chain formation comprises a Ze group and a $Wi\alpha$ group, or

the A-D and B-C chain formations each comprise a $Zi\beta$ group and a We group.

31. (new) The compound according to claim 29, of the following formulae:



or



32. (new) A complex between a compound according to claim 20, and a radioelement chosen from the α emitters, or a divalent or trivalent metallic element.

33. (new) A complex between a compound according to claim 20, and an α -emitter radioelement chosen from bismuth-212, bismuth-213, actinium-225, or astatine-211.

34. (new) A complex between a compound according to claim 20, and a divalent or trivalent metallic element chosen from Y(III), In(III), Cd(II), Mg(II), Mn(III), Fe(III), B(III) and the lanthanides.

35. (new) A pharmaceutical composition comprising a complex according to claim 32, in combination with a pharmaceutically acceptable vehicle.

36. (new) The pharmaceutical composition according to claim 35, wherein the composition is in a form that can be administered by intravenous route.

37. (new) The compound according to claim 20, wherein R_3 represents Na^+ or K^+ .

38. (new) The compound according to claim 20, wherein the alcohol depopulated of electrons is a para-nitro phenol group or the para-nitro phenol group.